Profile picture

Doctor Qidi Ying

Ningbo NO2 Hospital, Ningbo (China)
Follow
Logo ESC

Contributor content

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
Presentation
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
Read more

ESC 365 is supported by

novartis Explore sponsored resources